Table 2.

Adverse events

Empty Cell	Empty Cell	Semaglutide 2·4 mg group (n=47)	Placebo group (n=24)
On-treatment observation period, weeks		51·1 (9·9)	53·5 (5·9)
All patients with adverse events		42 (89%)	19 (79%)
Gastrointestinal disorders		36 (77%)	8 (33%)
	Nausea	21 (45%)	4 (17%)
	Diarrhoea	9 (19%)	2 (8%)
	Vomiting	8 (17%)	0 (0%)
	Abdominal pain	6 (13%)	1 (4%)
	Decreased appetite	6 (13%)	1 (4%)
	Eructation	6 (13%)	0 (0%)
	Abdominal pain upper	5 (11%)	2 (8%)
	Dyspepsia	5 (11%)	0 (0%)
Patients with other adverse events (≥10% in either treatment group)
	Urinary tract infection	3 (6%)	4 (17%)
	Back pain	0	3 (13%)
Patients with serious adverse events
	On-treatment	6 (13%)	2 (8%)
	In-trial	6 (13%)	2 (8%)
Serious adverse events
	Gastrointestinal disorders	3 (6%)	2 (8%)
	Eye disorders	1 (2%)	0
	Hepatobiliary disorders	1 (2%)	0
	Injury, poisoning, and procedural complications	1 (2%)	0
	Metabolism and nutrition disorders	1 (2%)	0
	Nervous system disorders	1 (2%)	0
	Renal and urinary disorders	1 (2%)	0
	Respiratory, thoracic, and mediastinal disorders	1 (2%)	0
	Musculoskeletal and connective tissues disorders	0	1 (4%)
	Psychiatric disorders	0	1 (4%)
	Fatal events	0	0
Severity*
	Mild	37 (79%)	17 (71%)
	Moderate	26 (55%)	10 (42%)
	Severe	8 (17%)	1 (4%)
Relationship to trial product*
	Probable	22 (47%)	4 (17%)
	Possible	23 (49%)	9 (38%)
	Unlikely	31 (66%)	18 (75%)
Leading to withdrawal of trial product		3 (6%)	0
Leading to withdrawal from trial		0	0

Data are n (%) unless otherwise stated. Data are from all exposed patients on treatment (safety analysis set). %=proportion of patients with at least one adverse event. Numbers are patients with at least one adverse event.

^*Patients could have more than one adverse event.